IP Library Granted Patent US 6,906,077
Granted Patent B1
US 6,906,077 · App. 09/856,987 · Granted Jun 14, 2005

Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,906,077
App. No.
09/856,987
Granted
Jun 14, 2005
Kind
B1
Abstract

Compositions and methods for the treatment of retina and optic nerve head neuropathy are disclosed. The compositions and methods are particularly directed to the use of neurotrophic factor stimulators, such as AIT-082 (neotrofin), in the treatment of glaucomatous neuropathy.

Claims (9)

1. A method for the treatment of retina or optic nerve head neuropathy associated with glaucoma which comprises administering to a mammal a composition comprising an effective amount of one or more non-peptide neurotrophic factor stimulator(s) and a pharmaceutically acceptable vehicle, wherein the non-peptide neurotrophic factor stimulator is selected from the group consisting of: AIT-082 (neotrofin), ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711 and clenbuterol, and wherein said composition is administered topically or intraocularly.

2. A method according to claim 1 , wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).

3. The method of claim 1 , wherein the composition is administered by intraocular injection prior to ocular surgery.

4. The method of claim 1 , wherein the composition is administered by intraocular injection during ocular surgery.

5. The method of claim 1 , wherein the composition is administered by intraocular injection prior to and during ocular surgery.

6. The method of claim 3 , wherein the composition is a balanced salt irrigating solution.

7. The method of claim 4 , wherein the composition is a balanced salt irrigating solution.

8. The method of claim 5 , wherein the composition is a balanced salt irrigating solution.

9. The method of claim 3 , wherein the composition is administered through retrobulbar or periocular injection.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS. PREVIOUSLY RECORDED AT REEL: 050746 FRAME: 0431. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.. Recorded Oct 18, 2019
From: ALCON RESEARCH, LLC
To: NOVARTIS AG
Reel/Frame 050767/0001 →
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Oct 17, 2019
From: ALCON RESEARCH, LLC
To: NOVARTIS AG
Reel/Frame 050746/0431 →
MERGER Recorded Oct 16, 2019
From: ALCON RESEARCH, LTD.
To: ALCON RESEARCH, LLC
Reel/Frame 050735/0465 →
MERGER Recorded Jul 21, 2008
From: ALCON MANUFACTURING, LTD.
To: ALCON RESEARCH, LTD.
Reel/Frame 021266/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2002
From: ALCON PHARMACEUTICALS, INC.
To: ALCON MANUFACTURING, LTD.
Reel/Frame 013378/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2002
From: ALCON LABORATORIES, INC.
To: ALCON PHARMACEUTICALS, INC.
Reel/Frame 013378/0978 →